PCI for Severe Calcification: Novel Device and Strategies in US Fashion - Flash Updates






Michael S. Lee, MD, FACC, FSCAl Associate Professor Interventional Cardiology


80 year-old diabetic with ACS














- Multiple, prolonged, highpressure inflations
- Unable to fully dilate balloon

- Slow flow
- Ischemia
- Contrast staining c/w dissection

- Cardiac arrest
- CPR

- Impella insertion
- Rotational atherectomy





- Intubated, multiple vaspressors
- Hemo-metabolic shock, septic shock, mult-organ failure
- Died

Coronary Artery Calcium a 40-year old problem

The New England Journal of Medicine

Copyright, 1979, by the Massachusetts Medical Society

Volume 301 JULY 12, 1979 Number 2

NONOPERATIVE DILATATION OF CORONARY-ARTERY STENOSIS


Percutaneous Transluminal Coronary Angioplasty

ANDREAS R. GRÜNTZIG, M.D., ÄKE SENNING, M.D., AND WALTER E. SIEGENTHALER, M.D.

'At present, the [balloon-dilatation] technique is limited by anatomic factors, such as ... calcified stenoses.'1

Challenges with Calcified Lesions


- Difficult to treat
 - Difficult to dilate
 - Prone to dissection during angioplasty
 - Difficulty delivering stent
 - Prevent adequate stent expansion
- Poor clinical outcomes, including higher MACE
 - Most trials excluded calcified lesions







Impact of Coronary Artery Calcification in PCI with PES ARRIVE I and II Registries







Rationale for Plaque Preparation with Coronary Atherectomy

- Improve procedural success
- Change morphology of lesion
- Facilitates optimal stent expansion
- Reduce complications






Orbital Atherectomy

Mechanism of Action







Differential Sanding:

- 30 micron diamond coating
- Bi-directional sanding, eccentric mounted crown
- Healthy elastic tissue flexes away minimizing damage to the vessel

Centrifugal Force:

- 360° crown contact designed to create a smooth, concentric lumen
- Allows constant blood flow and particulate flushing during orbit
- Increasing speed increases orbital diameter
- Ability to treat multiple vessel diameters with one crown (1.25 mm)
- Treat large vessels through small sheaths (6 French)






Single-Operator Technique






UCLA Health

76 y.o. male with unstable angina PMH: smoking, HTN











Angiography at 1 week shows pseudo-aneurysm of LAD

Difficulty wiring

Look, Listen, and Feel






- Advance 1 mm/second. Max 25 seconds
- Continue low-speed until change in cadence
- Slow, pecking. Never push

Final angiography

Treatment Algorithm







ORBIT II: Study Design

To evaluate safety and efficacy of the Diamondback Coronary OAS Classic Crown to prepare de novo, severely calcified coronary lesions for enabling stent placement

- Prospective, multi-center trial in the United States
- Single arm As there were no FDA-approved percutaneous treatments specifically for patients with severely calcified coronary lesions.
- 443 subjects enrolled at 49 U.S. Sites

30 day follow-up* (N=437/440)

1-year follow-up† (N=434/440)

2-year follow-up‡ (N=424/440)


(N=411/440)

- Primary Safety Endpoint: MACE (MI= CK-MB>3x ULN, TVR, Cardiac Death)
- Primary Efficacy Endpoint: Procedural Success
 Success in facilitating stent delivery with a final residual stenosis of <50% (as determined by Angiographic Core Lab) and free from in-hospital MACE



*438 subjects per Kaplan Meier were at risk/events for MACE †432 subjects per Kaplan Meier were at risk/events for MACE ‡411 subjects per Kaplan Meier were at risk/events for MACE #311 subjects per Kaplan Meier were at risk/events for MACE Lee MS, et al. Cardiovasc Revasc Med. 2017;18:261-264.

ORBIT II 3-Year TVR/TLR





Real-World Multicenter Experience on Patients with Severe **Coronary Artery Calcification Undergoing Orbital Atherectomy Participating Sites** St. Francis Hospi Retrospective study At the heart of health 458 consecutive patients with severe Health" CAC who underwent orbital atherectomy followed by stenting October 2013 to December 2015

Angiographic Complications

6 2016, Wiley Periodicals, Inc. DOI: 10.1111/joic.12310

ORIGINAL INVESTIGATION

Real-World Multicenter Registry of Patients with Severe Coronary Artery Calcification Undergoing Orbital Atherectomy

MICHAEL S. LEE, M.D., ¹ EVAN SHLOFMITZ, D.O., ² BARRY KAPLAN, M.D., ²
DRAGOS ALEXANDRU, M.D., ² PERWAIZ MERAJ, M.D., ² and RICHARD SHLOFMITZ, M.D. ³

From the ¹Division of Interventional Cardiology, UCLA Medical Center, Los Angeles, California; ²Division of Cardiology, Northwell Health, Manhasset, New York; and ³Division of Cardiology, St. Francis Hospital, Roslyn, New York

Objectives: We evaluated the safety and efficacy of orbital atherectomy in real-world patients with severe coronary artery calcification (CAC).

Background: The presence of severe CAC increases the complexity of percutaneous coronary intervention as it may impede stent delivery and optimal stent expansion. Atherectomy may be an indispensable tool for uncrossable or undilatable lesions by modifying severe CAC. Although the ORBIT I and II trials report that orbital atherectomy was safe and effective for the treatment of severe CAC, patients with kidney disease, recent myocardial infarction, long diffuse disease, severe left ventricular dysfunction, and unprotected left main disease were excluded.

Methods: This retrospective study included 458 consecutive patients with severe CAC who underwent orbital atherectomy followed by stenting from October 2013 to December 2015 at 3 centers.

Results: The primary endpoint of major adverse cardiac and cerebrovascular events at 30 days was 1.7%. Low rates of 30-day all-cause mortality (1.3%), myocardial infarction (1.1%), target vessel revascularization (0%), stroke (0.2%), and stent thrombosis (0.9%) were observed. Angiographic complications were low: perforation was 0.7%, dissection 0.9%, and no-reflow 0.7%. Emergency coronary artery bypass graft surgery was performed in 0.2% of patients.

Conclusion: In the largest real-world study of patients who underwent orbital atherectomy, including high-risk patients who were not surgical candidates as well as those with very complex coronary anatomy, acute and short-term adverse clinical event rates were low, A randomized clinical trial is needed to identify the ideal treatment strategy for patients with severe CAC. (3 Interven Cardiol 2016;9999:1–6)

	n=458
Perforation	3 (0.7%)
Dissection	4 (0.9%)
No reflow	3 (0.7%)





30-day Clinical Event Rates


	n=458
MACE	8 (1.7%)
Death	6 (1.3%)
Myocardial infarction	4 (1.1%)
Target vessel revascularization	0 (0.0%)
Stroke	1 (0.2%)
Stent thrombosis	4 (0.9%)
Emergent CABG	1 (0.2%)

Values are n (%)






Orbital Atherectomy for Unprotected Left Main Disease










Calcified Left Main and LAD





Orbital Atherectomy Left Main Artery







Treats 360° of the vessel. The diamond coated crown sands away calcium and allows healthy elastic tissue to flex away minimizing injury to the vessel.





Final Angiography









Conclusion

- Coronary artery calcification may prevent stent delivery and optimal stent expansion
- CAC is associated with increased risk of complications, including death, MI, TVR, and stent thrombosis
- Orbital atherectomy is a safe and effective treatment strategy for patients with severe CAC
- Low angiographic complications
- Acceptable rates of TVR







John Wooden

"Failing to prepare is preparing to fail"



